Biorchestra Co. Ltd. reached an exclusive research, option and licensing contract with a U.S.-based company to use its targeting technology platform to develop nucleic acid therapies to treat neurological disorders in a deal valued up to $861 million.

Boehringer Ingelheim GmbH has agreed to pay Covant Therapeutics Inc. $10 million for exclusive rights to the latter’s ADAR1-targeting immuno-oncology program. Under the terms of the exclusive research collaboration and worldwide licensing agreement, newly unveiled drug discovery company Covant will carry out the preclinical work in creating an ADAR1 small-molecule inhibitor, with Boehringer offering its scientific expertise to help advance the program into the clinic.

Biohaven Ltd. has acquired global rights, excluding China, from Highlightll Pharmaceutical Co. Ltd. to develop and commercialize a dual inhibitor of tyrosine kinase 2 (TYK2) and JAK1, BHV-8000 (TLL-041), for the treatment of brain disorders in a deal worth up to $970 million.

Triastek Inc., a digital pharmaceutical solutions company, is taking a unique approach by using 3D printing technology to develop a pipeline that spans rheumatoid arthritis (RA), clotting disorders, ulcerative colitis and pulmonary hypertension. Its technology was recently validated through a partnership with Boehringer Ingelheim GmbH. The company’s 3D printing products include T-19, T-20 and T-21, which have all received IND approval from the FDA.

Jounce Therapeutics Inc. is leaving Redx Pharma plc at the altar after deciding instead to merge with Concentra Biosciences LLC. In late February, Jounce had said it planned to merge with Redx in an all-share transaction that would have created a $425 million combined entity.

Bellaseno GmbH and Evonik Industries AG joined forces to commercialize 3D-printed scaffolds used in bone regeneration. The scaffolds are made with Evonik’s Resomer polymers to address large and complex bone defects as an alternative to frequently less stable conventional methods.